Sergey Yurasov
Chief Medical OfficerDr. Sergey Yurasov, M.D., Ph.D., serves as Chief Medical Officer at Black Diamond Therapeutics, Inc. since June 2022. He joined Black Diamond Therapeutics, Inc. in June 2022. Dr. Yurasov was Chief Medical Officer of Nuvation Bio, Inc. since September 2019. He had been Chief Medical Officer and Senior Vice President of Clinical Development at Immune Design Corp. since October 4, 2016 until July 2019. Dr. Yurasov served at Clovis Oncology as Senior Vice President of Clinical Development since August 2014 until September 2016. Dr. Yurasov served as an Associate Vice-President of Global Medicine Science at ImClone Systems, a subsidiary of Eli Lilly & Co. where he led the development of ramucirumab culminating in the FDA submission for second line non-small cell lung cancer indication. He held various positions of increasing responsibility at ImClone Systems Incorporated since August 2010 until August 2014. He also served at Hoffman-La Roche as Clinical Director of Oncology, Pharma Research and Early Development at Hoffman-La Roche. Prior to his industry experience, Dr. Yurasov served as an Assistant Professor of Clinical Investigation at ical Instructity, where he was the Principal investigator for NIH funded translational immunology research and Clinical Instructor in the Department of Pediatrics at Memorial Sloan-Kettering Cancer Center, where he was an attending physician. Dr. Yurasov has an extensive experience and successful track record in immunology and in the various stages of clinical oncology drug development, including registration trials and regulatory submissions and reviews. He has an esteemed career as an immunologist and oncologist spans industry, academia and clinical practice and has an invaluable expertise and insight. He is a board-certified, U.S. licensed hematologist/oncologist with experience in immunology and oncology. He thereafter completed his residency in general pediatrics at Albert Einstein College of Medicine, Jacobi Medical Center and has subspecialty training in pediatric hematology/oncology at Memorial Sloan-Kettering Cancer Center. He was a Research Fellow at The Rockefeller University in Dr. M. Nussenzweig's laboratory. He has a M.D. from the Russian State Medical University and has a Ph.D. in Medical Sciences from the Research Institute for Pediatric Oncology in Moscow, Russia.
Positions
- Company NameBlack Diamond Therapeutics, Inc.Stock CodeBDTXPositionChief Medical OfficerColleagues
- MAMark A. VellecaCEO, President & Chairman
- BHBrent Hatzis-SchochCOO & General Counsel
- EBElizabeth BuckCo-Founder & Chief Scientific Officer
- EJErika JonesPrincipal Financial Officer, Principal Accounting Officer, SVP of Finance & Corporate Controller
- ABAli BehbahaniIndependent Director
- GEGarry E. MenzelIndependent Director
- KDKapil DhingraIndependent Director
- SKSamarth KulkarniLead Independent Director
